ALK and non-small cell lung carcinoma: A higher frequency of brain metastasis was noted at initial diagnosis in RET+ NSCLC compared to ROS1+ NSCLC (RET: 32% vs ROS1: 10%; p = 0.039); however, the frequency of brain metastasis at initial diagnosis was not significantly different between RET+ and ALK+ NSCLC (RET: 32% vs ALK: 25%; p = 0.592).